# Clinical Trial to Evaluate the Efficacy of Treatment With Hyperimmune Plasma Obtained From Convalescent Antibodies of COVID-19 Infection

> **NCT04366245** · PHASE1,PHASE2 · COMPLETED · sponsor: **Andalusian Network for Design and Translation of Advanced Therapies** · enrollment: 72 (actual)

## Conditions studied

- SARS-CoV 2

## Interventions

- **BIOLOGICAL:** Hyperimmune plasma
- **DRUG:** Standard of care for SARS-CoV-2 infection

## Key facts

- **NCT ID:** NCT04366245
- **Lead sponsor:** Andalusian Network for Design and Translation of Advanced Therapies
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-04-23
- **Primary completion:** 2020-12-30
- **Final completion:** 2020-12-30
- **Target enrollment:** 72 (ACTUAL)
- **Last updated:** 2022-04-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04366245

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04366245, "Clinical Trial to Evaluate the Efficacy of Treatment With Hyperimmune Plasma Obtained From Convalescent Antibodies of COVID-19 Infection". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT04366245. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*